Capecitabine is an oral chemotherapy agent classified under Oncology Support. It is supplied as a pill in a 500 mg strength. In Hong Kong, capecitabine is a prescription-only medication and is regulated by the Hong Kong Department of Health. The drug is used primarily for the treatment of several solid tumours and is available from various manufacturers under the same generic name.
Capecitabine is a prodrug that is converted into the active chemotherapy agent 5-fluorouracil (5-FU) after oral absorption. The conversion occurs in three enzymatic steps:
Because 5-FU is generated preferentially in cancer cells, capecitabine provides a degree of tumour selectivity. Once formed, 5-FU inhibits thymidylate synthase, disrupting DNA synthesis and leading to cancer cell death. The drug’s onset of action typically occurs within a few days after the first dose, with peak plasma concentrations of 5-FU appearing after 1-2 hours of capecitabine ingestion. The pharmacologic effect persists for the duration of the treatment cycle, which is usually followed by a rest period.
Capecitabine has received regulatory approval for several oncology indications. In Hong Kong, the approved uses align closely with those granted by major agencies such as the U.S. FDA and the European EMA:
The drug is prescribed for adult patients with measurable disease who meet specific clinical criteria, such as adequate organ function and performance status. Dosing is individualized based on body surface area (BSA) and the chosen treatment schedule.
Research studies have explored capecitabine in additional tumour types, including:
These applications are not approved by regulatory agencies in Hong Kong. Off-label use requires careful risk-benefit assessment by a qualified oncologist and close monitoring for toxicity.
When uncertainty exists, clinicians should refer to local guidelines and consider genetic testing for DPD deficiency before initiating therapy.
Regular monitoring is essential to ensure efficacy while minimizing toxicity:
Patients should contact their oncology team if they experience fever, persistent diarrhoea, severe hand-foot reaction, or any new neurological symptoms.
This article provides educational information about capecitabine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Severe (grade 3-4) hand-foot syndrome requires prompt evaluation by your oncology team. Dose interruption, reduction, or temporary discontinuation is often recommended, and supportive measures such as topical emollients, cooling packs, and pain control may be employed.
Capecitabine may be taken with or without food. Consistency is key-choose one method and maintain it throughout the treatment cycle to avoid fluctuations in absorption. Food does not markedly diminish the drug’s efficacy but can lessen gastrointestinal irritation.
The dose is individualized based on body surface area (BSA), which is derived from height and weight using standard formulas. The prescribing oncologist converts the BSA-based milligram prescription into the corresponding number of 500 mg tablets.
Vaccination against COVID-19 is generally recommended for patients receiving chemotherapy, including capecitabine. Timing should be coordinated with the oncology team to avoid overlapping peak immunosuppression periods.
Capecitabine does not have a direct pharmacokinetic interaction with most antihypertensive agents. However, any new or worsening side effects, such as dehydration from diarrhoea, could affect blood pressure control, so monitoring is advisable.
Signs include severe nausea, vomiting, diarrhoea, and dramatically low blood counts. Emergency medical care is required; treatment focuses on supportive hydration, anti-emetics, and, when appropriate, leucovorin rescue to mitigate fluoropyrimidine toxicity.
Capecitabine is a prescription-only medication. Carry the original prescription label, a copy of the prescribing doctor’s note, and keep the tablets in their original packaging. Check the destination country’s import regulations; many require a medical certificate for chemotherapy agents.
Both brand-name and generic capecitabine contain the same active ingredient and are required to meet identical bioequivalence standards. Clinical efficacy and safety are expected to be comparable when manufactured according to regulatory guidelines.
Shelf life is typically 24 months from the date of manufacture when stored at room temperature, protected from moisture and light. Always verify the expiration date on the packaging before use.
Do not flush the medication or throw it in regular household waste. Return unused tablets to a pharmacy dispensing take-back programme or follow Hong Kong’s pharmaceutical waste disposal instructions to prevent accidental exposure.
